What is the role of Vitamin B6 (pyridoxine) in patients undergoing chronic hemodialysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vitamin B6 (Pyridoxine) in Chronic Hemodialysis

Vitamin B6 (pyridoxine) is a water-soluble vitamin essential for amino acid metabolism, neurotransmitter synthesis, and hemoglobin production, and hemodialysis patients require daily supplementation of 10 mg pyridoxine hydrochloride because dialysis removes the vitamin and dietary intake alone cannot maintain adequate levels. 1

What is Vitamin B6

Vitamin B6 exists as multiple forms (vitamers) including pyridoxine, pyridoxal, and pyridoxamine, with pyridoxal 5-phosphate (PLP) being the active coenzyme form used throughout the body. 2 The vitamin has no body stores, making continuous dietary intake or supplementation essential. 2 Normal plasma PLP levels range from 5-50 mg/L (20-200 nmol/L). 2

Why Hemodialysis Patients Develop Deficiency

  • Dialysis removal: Hemodialysis physically removes vitamin B6 from the blood during treatment, creating ongoing losses that dietary intake cannot replace. 3, 1

  • Inadequate dietary intake: Patients with chronic kidney disease consuming low-protein diets typically ingest only 1.3 mg/day of vitamin B6, which is insufficient even without dialysis losses. 4

  • Increased requirements: The standard recommended dietary allowance (RDA) for healthy adults is only 1.3-1.7 mg/day, but this does not account for dialysis losses. 2

Evidence for Supplementation Requirements

Hemodialysis patients should receive 10 mg/day of supplemental pyridoxine hydrochloride (equivalent to 8.2 mg/day of pyridoxine base) to correct and maintain normal vitamin B6 status. 1 This recommendation comes from a study of 37 patients with chronic renal failure and 71 patients on maintenance dialysis that systematically tested doses from 1.25 to 50 mg/day. 1

Dose-Response Evidence

  • Inadequate doses: Supplements of 5 mg/day or less frequently failed to correct vitamin B6 deficiency, particularly in patients with infections or taking medications that antagonize vitamin B6 (isoniazid, penicillamine, anticonvulsants, corticosteroids). 1

  • Effective doses: Both 10 mg/day and 50 mg/day rapidly corrected abnormal vitamin B6 status and maintained normal values in all hemodialysis patients. 1

  • Optimal dose selection: The 10 mg/day dose is preferred as the lowest effective dose that reliably corrects deficiency. 1

Special Circumstances Requiring Higher Doses

Increase supplementation to 20 mg/day of pyridoxine in hemodialysis patients receiving erythropoietin (EPO) therapy. 5 Indirect evidence demonstrates that erythrocyte vitamin B6 is consumed more rapidly during hemoglobin synthesis stimulated by EPO treatment. 5

Additional Indications for Higher Doses

  • Active infection/sepsis: During septic episodes, 10 mg/day may be insufficient; consider maintaining this as the minimum dose. 1

  • Medication interactions: Patients taking vitamin B6 antagonists (isoniazid, penicillamine, anti-cancer drugs, corticosteroids, anticonvulsants) require at least 10 mg/day. 2, 1

  • Furosemide use: This diuretic increases urinary excretion and fractional excretion of vitamin B6, potentially increasing requirements. 5

Peritoneal Dialysis Patients

Patients on continuous ambulatory peritoneal dialysis (CAPD) require 5-10 mg/day of supplemental pyridoxine hydrochloride. 4, 1 Peritoneal losses are relatively small (8 nmol PLP/day), but dietary intake alone remains insufficient. 4

  • Most CAPD patients achieve adequate repletion with 5 mg/day oral pyridoxine hydrochloride. 4

  • Some patients require 10 mg/day to achieve normal plasma PLP levels. 4

  • Without EPO treatment, 6 mg/day was optimal during 12 months of CAPD therapy. 5

  • With EPO treatment, increase to 20 mg/day. 5

Monitoring Vitamin B6 Status

Measure plasma pyridoxal 5-phosphate (PLP) levels using HPLC with fluorescence detection or tandem mass spectrometry. 2 Blood samples require rapid plasma separation and frozen storage because PLP degrades at room temperature and with light exposure. 2

When Plasma Measurements Are Unreliable

  • Inflammation or low albumin: In these conditions, measure red blood cell PLP instead of plasma PLP, as inflammation causes plasma PLP to fall independent of true vitamin B6 status. 2

  • Altered alkaline phosphatase: Red cell measurements are more reliable when alkaline phosphatase activity is abnormal. 2

Critical Safety Considerations

The 10 mg/day supplementation dose for hemodialysis patients is far below the toxicity threshold and is safe for long-term use. 2, 6 However, clinicians must understand the boundaries:

  • Tolerable upper limit: 100 mg/day for adults aged 19-70 years, though even this dose has caused toxicity with prolonged use. 2, 6

  • Documented toxicity: Prolonged intake of 300 mg/day causes sensory neuropathy, and even 100 mg/day long-term has been associated with neurological complications including Lhermitte signs. 6, 7

  • Toxicity symptoms: Numbness/paresthesia in extremities, loss of distal sensation, motor ataxia, weakness, loss of deep tendon reflexes, and muscle atrophy. 8

Common Pitfalls to Avoid

  • Assuming dietary intake is adequate: Even without dialysis, patients with chronic kidney disease on low-protein diets consume insufficient vitamin B6. 4

  • Using doses below 10 mg/day in hemodialysis: Lower doses frequently fail to maintain normal status, particularly during illness. 1

  • Forgetting to increase dose with EPO: Erythropoietin therapy substantially increases vitamin B6 consumption for hemoglobin synthesis. 5

  • Not checking medication lists: Multiple common medications antagonize vitamin B6 and increase requirements. 2, 1

  • Measuring plasma PLP during inflammation: Use red blood cell PLP measurements instead when albumin is low or inflammation is present. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Vitamin B6 status in uremia.

Klinische Wochenschrift, 1990

Guideline

Treatment of Vitamin B6 Toxicity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Vitamin B6 for Akathisia: Safety Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Vitamin B6 Elevation Causes and Implications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.